What is it about?
Based on a large clinical sample of type 2 diabetes or cardiometabolic disease patients from meta-analyses of RCTs, GLP-1 RA was not found to be related to the risk of optic nerve/ vision-threatening events.
Featured Image
Why is it important?
Systematic review of randomised trial evidence on any relations between GLP-1 RA and vision-threatening complications had been lacking.
Perspectives
Potential risks versus benefits of GLP-1 receptor agonists require careful evaluations and individualised assessments.
Dr. Yap-Hang Will Chan
University of Hong Kong
Read the Original
This page is a summary of: GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials, Diabetes Care, January 2026, American Diabetes Association,
DOI: 10.2337/dc25-1929.
You can read the full text:
Contributors
The following have contributed to this page
